Press Release

Massive Bio Nominated for Prestigious Digital Health Award


Massive Bio has been named a quarterfinalist in the annual UCSF | Health Hub: Digital Health Awards, which recognize health tech companies that are driving innovation and improving delivery of healthcare.

Massive Bio has been named a Best in Class Quarterfinalist in the UCSF | Health Hub: Digital Health Awards competition. These prestigious awards are granted annually by UCSF Health Hub (a non-profit organization affiliated with the University of California San Francisco) to recognize “the achievements of innovative health tech companies that are dramatically improving healthcare through the use of technology in the digital health industry.”

More than 1,250 companies entered the UCSF | Health Hub: Digital Health Awards competition this year. Massive Bio was chosen by a panel of over 1,000 experts from industry and academia as one of 16 quarterfinalists in the “New Health Application of AI” category, which honors excellence in the use of artificial intelligence to improve the quality, reliability, and cost-efficiency of healthcare. Massive Bio’s unique artificial intelligence-driven platform, SYNERGY-AI, rapidly matches cancer patients to clinical trials of promising new oncology therapies. The company’s mission is to remove barriers to clinical trials for patients in need of advanced treatments and increase efficiency of drug development for the pharmaceutical industry.

“This nomination represents an important milestone for Massive Bio, being recognized as a major player in the digital health space at a global level, and we are honored and humbled to be listed amongst the ‘best in class’ in the industry,” said Arturo Loaiza-Bonilla, MD, Massive Bio co-founder and chief medical officer. “Our AI-enabled technology is well positioned to optimize clinical workflows, advancing precision medicine and novel approaches to oncology research such as just-in-time, decentralized clinical trials, and digitally enabled patient-centric solutions. This recognition is a great validation of our approach and current and potential impact.” 

“This recognition is a testament to the hard work of all our team and those who believe in our mission to make clinical trials accessible to all cancer patients,” added Selin Kurnaz, co-founder and CEO of Massive Bio. “We want to make sure this novel, scalable use case of AI helps patients across the globe find personalized clinical trial options, in real time, to treat their cancer.”

Finalists for the UCSF | Health Hub: Digital Health Awards will be announced on October 21, with the winners revealed at the grand finale of the 2022 HLTH conference in Las Vegas on November 14.

Learn more about the UCSF | Health Hub: Digital Health Awards here.

Don't forget to share this post!